Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.
Wong
Victoria S S
VS
D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D017028:Caregivers / Q000523:psychology; D002986:Clinical Trials as Topic / Q000941:ethics / Q000592:standards; D004185:Disability Evaluation; D005702:Galantamine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008569:Memory Disorders / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000009:adverse effects / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care / Q000941:ethics / Q000592:standards*; D011788:Quality of Life; D012141:Respiratory Tract Infections / Q000139:chemically induced; D018570:Risk Assessment; D013064:Speech Disorders / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome; D014705:Verbal Behavior / Q000187:drug effects / Q000502:physiology; D014839:Vomiting / Q000139:chemically induced
D018697:Nootropic Agents; D005702:Galantamine